Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
In the coming weeks, several Israeli life sciences companies will examine whether the Nasdaq primary market is still hot. The largest offering will apparently be made by burn and wound treatment company MediWound Ltd., controlled by Clal Biotechnology Industries Ltd. (TASE: CBI) with a 64% stake. On Sunday, MediWound announced that it had filed a draft prospectus for an offering on Nasdaq.
Following the announcement, the share price of Clal Biotech, controlled by Len Blavatnik, rose 5.2%, and rose a further 0.6% in morning trading today. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) owns 14% of Clal Biotech.
Using pineapple to treat burns
A year ago, MediWound obtained marketing approval for its burn treatment in Europe, and it began sales a month ago. In the US, the company is preparing for a multi-center trial. The product is a gel made of a mixture of enzymes which are extracted from the stem of the pineapple plant. The gel removes eschar, the necrotic tissue that covers severe burn wounds (burn cleaning), to encourage healing.
Published by Globes [online], Israel business news – www.globes-online.com